LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 56

Search options

  1. Article ; Online: Headaches During COVID-19: My Clinical Case and Review of the Literature.

    Belvis, Robert

    Headache

    2020  Volume 60, Issue 7, Page(s) 1422–1426

    Abstract: Objective: To analyze headaches related to COVID-19 based on personal case experience.: Background: COVID-19 is an infection caused by the new coronavirus SARS-CoV-2. The first reported case happened in Wuhan on December 1, 2019. At present, at least ...

    Abstract Objective: To analyze headaches related to COVID-19 based on personal case experience.
    Background: COVID-19 is an infection caused by the new coronavirus SARS-CoV-2. The first reported case happened in Wuhan on December 1, 2019. At present, at least 1.8 million people are infected around the world and almost 110,000 people have died. Many studies have analyzed the clinical picture of COVID-19, but they are focused on respiratory symptoms and headache is generically treated.
    Methods: I describe and discuss my headaches during my COVID-19 and I review the MEDLINE literature about headaches and COVID-19.
    Results: More than 41,000 COVID-19 patients have been included in clinical studies and headache was present in 8%-12% of them. However, no headache characterization was made in these studies. As a headache expert and based on my own personal clinical case, headaches related to COVID-19 can be classified in the 2 phases of the disease. Acute headache attributed to systemic viral infection, primary cough headache, tension-type headache and headache attributed to heterophoria can appear in the first phase (the influenza-like phase); and headache attributed to hypoxia and a new headache, difficult to fit into the ICHD3, can appear if the second phase (the cytokine storm phase) occurs.
    Conclusions: Several headaches can appear during COVID-19 infection. All of them are headaches specified in the ICHD3, except 1 that occurs from the 7th day after the clinical onset. This headache is probably related to the cytokine storm that some patients suffer and it could be framed under the ICHD3 headache of Headache attributed to other non-infectious inflammatory intracranial disease. Although the reported prevalence of headaches as a symptom of COVID-19 infection is low, this experience shows that, very probably, it is underestimated.
    MeSH term(s) COVID-19/complications ; Headache/virology ; Humans ; Male ; Middle Aged ; SARS-CoV-2
    Keywords covid19
    Language English
    Publishing date 2020-05-15
    Publishing country United States
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 410130-3
    ISSN 1526-4610 ; 0017-8748
    ISSN (online) 1526-4610
    ISSN 0017-8748
    DOI 10.1111/head.13841
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Headaches During COVID‐19

    Belvis, Robert

    Headache: The Journal of Head and Face Pain

    My Clinical Case and Review of the Literature

    2020  Volume 60, Issue 7, Page(s) 1422–1426

    Keywords Neurology ; Clinical Neurology ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    ZDB-ID 410130-3
    ISSN 1526-4610 ; 0017-8748
    ISSN (online) 1526-4610
    ISSN 0017-8748
    DOI 10.1111/head.13841
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Headaches During COVID-19: My Clinical Case and Review of the Literature

    Belvis, Robert

    Headache

    Abstract: OBJECTIVE: To analyze headaches related to COVID-19 based on personal case experience. BACKGROUND: COVID-19 is an infection caused by the new coronavirus SARS-CoV-2. The first reported case happened in Wuhan on December 1, 2019. At present, at least 1.8 ... ...

    Abstract OBJECTIVE: To analyze headaches related to COVID-19 based on personal case experience. BACKGROUND: COVID-19 is an infection caused by the new coronavirus SARS-CoV-2. The first reported case happened in Wuhan on December 1, 2019. At present, at least 1.8 million people are infected around the world and almost 110,000 people have died. Many studies have analyzed the clinical picture of COVID-19, but they are focused on respiratory symptoms and headache is generically treated. METHODS: I describe and discuss my headaches during my COVID-19 and I review the MEDLINE literature about headaches and COVID-19. RESULTS: More than 41,000 COVID-19 patients have been included in clinical studies and headache was present in 8%-12% of them. However, no headache characterization was made in these studies. As a headache expert and based on my own personal clinical case, headaches related to COVID-19 can be classified in the 2 phases of the disease. Acute headache attributed to systemic viral infection, primary cough headache, tension-type headache and headache attributed to heterophoria can appear in the first phase (the influenza-like phase); and headache attributed to hypoxia and a new headache, difficult to fit into the ICHD3, can appear if the second phase (the cytokine storm phase) occurs. CONCLUSIONS: Several headaches can appear during COVID-19 infection. All of them are headaches specified in the ICHD3, except 1 that occurs from the 7th day after the clinical onset. This headache is probably related to the cytokine storm that some patients suffer and it could be framed under the ICHD3 headache of Headache attributed to other non-infectious inflammatory intracranial disease. Although the reported prevalence of headaches as a symptom of COVID-19 infection is low, this experience shows that, very probably, it is underestimated.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #277014
    Database COVID19

    Kategorien

  4. Article ; Online: Benito's neuralgia: the first description of the occipital neuralgia was made for Spanish doctors at the beginning of the nineteenth century.

    Belvís, Robert / Guerrero, Ángel L

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

    2019  Volume 40, Issue 11, Page(s) 2425–2429

    Abstract: Background: The occipital neuralgia affects 3 out of every 100,000 people and includes the neuralgia of the greater occipital nerve (GON) and the neuralgia of the minor and third occipital nerves. These nerves emerge from the posterior branches of the ... ...

    Abstract Background: The occipital neuralgia affects 3 out of every 100,000 people and includes the neuralgia of the greater occipital nerve (GON) and the neuralgia of the minor and third occipital nerves. These nerves emerge from the posterior branches of the first cervical roots, innervate the muscles of the nape, and provide the sensitivity of the scalp. The most frequent issue is not to find causes that justify neuralgia for what is usually idiopathic. The nerve that most often causes neuralgia is the GON that is usually wrongly called Arnold's nerve, so neuralgia is also called Arnold's neuralgia.
    Methods: We have reviewed the first description of occipital neuralgia.
    Results: Two Spanish doctors, José Benito Lentijo and Mateo Martínez Ramos, had already described in detail the neuralgia of the GON before Arnold was born. The first clinical case of occipital neuralgia due to GON involvement was published by them in a Spanish medical journal in 1821, and they called it cervico-suboccipital neuralgia.
    Conclusion: We claim in this article the role of these two Spanish doctors in the history of Neurology.
    MeSH term(s) Headache Disorders/history ; History, 19th Century ; Humans ; Neuralgia/history ; Spain ; Spinal Nerves/physiopathology
    Language English
    Publishing date 2019-02-15
    Publishing country Italy
    Document type Historical Article ; Journal Article
    ZDB-ID 2016546-8
    ISSN 1590-3478 ; 1590-1874
    ISSN (online) 1590-3478
    ISSN 1590-1874
    DOI 10.1007/s10072-019-03734-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Thrombolysis for acute stroke in pediatrics.

    Belvís, Robert

    Stroke

    2007  Volume 38, Issue 6, Page(s) 1722–1723

    MeSH term(s) Child ; Humans ; Pediatrics/methods ; Pediatrics/trends ; Stroke/drug therapy ; Thrombolytic Therapy/adverse effects ; Thrombolytic Therapy/methods ; Thrombolytic Therapy/trends
    Language English
    Publishing date 2007-06
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 80381-9
    ISSN 1524-4628 ; 0039-2499 ; 0749-7954
    ISSN (online) 1524-4628
    ISSN 0039-2499 ; 0749-7954
    DOI 10.1161/STROKEAHA.107.487116
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Migraine treatment consensus document of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment.

    Belvís, Robert / Irimia, Pablo / González, Nuria / García-Ull, Jésica / Pozo-Rosich, Patricia / López-Bravo, Alba / Morollón, Noemí / Quintas, Sonia / Plana, Antoni / Baz, Pablo Gregorio / Tentor, Ana / Gallego Artiles, Natalia / León, Francisco Javier / Pérez Martín, Miguel / Rivera, Inés / Ramírez, Raquel / Colomina, Isabel / Lainez, José Miguel / Pascual, Julio

    Medicina clinica

    2024  

    Abstract: Migraine is a disease with a high prevalence and incidence, in addition to being highly disabling, causing a great impact on the patient's quality of life at a personal, family and work level, but also social, given its high expense due to its direct ( ... ...

    Title translation Documento de consenso de la Sociedad Española de Neurología (SEN), Sociedad Española de Medicina de Familia y Comunitaria (SEMFYC), Sociedad de Medicina de Atención Primaria (SEMERGEN) y Asociación Española de Migraña y Cefalea (AEMICE) sobre el tratamiento de la migraña.
    Abstract Migraine is a disease with a high prevalence and incidence, in addition to being highly disabling, causing a great impact on the patient's quality of life at a personal, family and work level, but also social, given its high expense due to its direct (care) and indirect (presenteeism and work absenteeism) costs. The multiple and recent developments in its pathophysiological knowledge and in its therapy require updating and, therefore, in this article the Spanish scientific societies most involved in its study and treatment (SEN, SEMFYC and SEMERGEN), together with the Association Spanish Association for Patients with Migraine and other Headaches (AEMICE), we have developed these updated care recommendations. We reviewed the treatment of migraine attacks, which consisted mainly of the use of NSAIDs and triptans, to which ditans and gepants have been added. We also discuss preventive treatment consisting of oral preventive drugs, botulinum toxin, and treatments that block the action of calcitonin-related peptide (CGRP). Finally, we emphasize that pharmacological treatments must be complementary to carrying out general measures consisting of identifying and managing/deletion the precipitating factors of the attacks and the chronicizing factors, controlling the comorbidities of migraine and eliminating analgesic overuse.
    Language Spanish
    Publishing date 2024-04-19
    Publishing country Spain
    Document type Practice Guideline
    ZDB-ID 411607-0
    ISSN 1578-8989 ; 0025-7753
    ISSN (online) 1578-8989
    ISSN 0025-7753
    DOI 10.1016/j.medcli.2024.02.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Cutaneous Allodynia in Migraine: A Narrative Review.

    Mínguez-Olaondo, Ane / Quintas, Sonia / Morollón Sánchez-Mateos, Noemí / López-Bravo, Alba / Vila-Pueyo, Marta / Grozeva, Vesselina / Belvís, Robert / Santos-Lasaosa, Sonia / Irimia, Pablo

    Frontiers in neurology

    2022  Volume 12, Page(s) 831035

    Abstract: Objective: In the present work, we conduct a narrative review of the most relevant literature on cutaneous allodynia (CA) in migraine.: Background: CA is regarded as the perception of pain in response to non-noxious skin stimulation. The number of ... ...

    Abstract Objective: In the present work, we conduct a narrative review of the most relevant literature on cutaneous allodynia (CA) in migraine.
    Background: CA is regarded as the perception of pain in response to non-noxious skin stimulation. The number of research studies relating to CA and migraine has increased strikingly over the last few decades. Therefore, the clinician treating migraine patients must recognize this common symptom and have up-to-date knowledge of its importance from the pathophysiological, diagnostic, prognostic and therapeutic point of view.
    Methods: We performed a comprehensive narrative review to analyze existing literature regarding CA in migraine, with a special focus on epidemiology, pathophysiology, assessment methods, risk for chronification, diagnosis and management. PubMed and the Cochrane databases were used for the literature search.
    Results: The prevalence of CA in patients with migraine is approximately 60%. The mechanisms underlying CA in migraine are not completely clarified but include a sensitization phenomenon at different levels of the trigemino-talamo-cortical nociceptive pathway and dysfunction of brainstem and cortical areas that modulate thalamocortical inputs. The gold standard for the assessment of CA is quantitative sensory testing (QST), but the validated Allodynia 12-item questionnaire is preferred in clinical setting. The presence of CA is associated with an increased risk of migraine chronification and has therapeutic implications.
    Conclusions: CA is a marker of central sensitization in patients with migraine that has been associated with an increased risk of chronification and may influence therapeutic decisions.
    Language English
    Publishing date 2022-01-21
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2564214-5
    ISSN 1664-2295
    ISSN 1664-2295
    DOI 10.3389/fneur.2021.831035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Treatment of chronic migraine with intramuscular pericranial injections of onabotulinumtoxin a.

    Belvis, Robert / Mas, Natalia

    Recent patents on CNS drug discovery

    2014  Volume 9, Issue 3, Page(s) 181–192

    Abstract: Chronic migraine is the most frequent and disabling complication of migraine. To date, only two drugs have been specifically analysed for the treatment of chronic migraine, topiramate and onabotulinumtoxin A, and in the evidence-based medicine categories, ...

    Abstract Chronic migraine is the most frequent and disabling complication of migraine. To date, only two drugs have been specifically analysed for the treatment of chronic migraine, topiramate and onabotulinumtoxin A, and in the evidence-based medicine categories, they have achieved level of evidence I and as such, a grade of recommendation A according to current guidelines. Following the PREEMPT paradigm, pericranial intramuscular onabotulinumtoxin A injections show a good efficacy and safety in chronic migraine patients, both in phase III randomized clinical trials and in a pooled data analyses. Onabotulinumtoxin A injections reduce the number of days of headache and migraine, they reduce the consumption of triptans and disability, and improve the quality of life of migraine patients. For these reasons, onabotulinumtoxin type A is an option as valid as topiramate for the treatment of chronic migraine.
    MeSH term(s) Adult ; Botulinum Toxins, Type A/administration & dosage ; Botulinum Toxins, Type A/therapeutic use ; Chronic Disease ; Double-Blind Method ; Female ; Humans ; Injections, Intramuscular ; Male ; Migraine Disorders/drug therapy ; Treatment Outcome
    Chemical Substances Botulinum Toxins, Type A (EC 3.4.24.69)
    Language English
    Publishing date 2014-12-30
    Publishing country United Arab Emirates
    Document type Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 2253602-4
    ISSN 2212-3954 ; 1574-8898
    ISSN (online) 2212-3954
    ISSN 1574-8898
    DOI 10.2174/1574889810666150131124603
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms.

    Calabria, Marco / García-Sánchez, Carmen / Grunden, Nicholas / Pons, Catalina / Arroyo, Juan Antonio / Gómez-Anson, Beatriz / Estévez García, Marina Del Carmen / Belvís, Roberto / Morollón, Noemí / Vera Igual, Javier / Mur, Isabel / Pomar, Virginia / Domingo, Pere

    Journal of neurology

    2022  Volume 269, Issue 8, Page(s) 3990–3999

    Abstract: Fatigue in its many forms of physical, mental, and psychosocial exhaustion is a common symptom of post-COVID-19 condition, also known as "Long COVID." Persistent fatigue in COVID-19 patients is frequently accompanied by cognitive dysfunction and ... ...

    Abstract Fatigue in its many forms of physical, mental, and psychosocial exhaustion is a common symptom of post-COVID-19 condition, also known as "Long COVID." Persistent fatigue in COVID-19 patients is frequently accompanied by cognitive dysfunction and neuropsychiatric symptoms; however, less is known about the relationships between these components of post-COVID-19 condition and fatigue itself. Consequently, the present study sought to (1) distinguish the types of fatigue experienced by participants, and (2) investigate whether cognitive deficits across various domains and neuropsychiatric conditions predicted these different types of fatigue. The study included 136 COVID-19 patients referred for neuropsychological evaluation due to cognitive complaints 8 months on average after SARS-CoV-2 infection. Measures included self-reported fatigue (physical, cognitive, and psychosocial), neuropsychiatric questionnaires (assessing symptoms of depression, anxiety, apathy, and executive functioning), a comprehensive neuropsychological assessment, and self-reported quality of life and everyday functioning. Results showed that reports of clinical significant fatigue were pervasive in our sample (82.3% of participants), with physical fatigue rated highest on average relative to the subscale maximum. Elevated levels of apathy, anxiety, and executive dysfunction in neuropsychiatric measures along with executive and attentional difficulties on cognitive tests were found to be consistently important predictors among different types of fatigue. This implicates both cognitive and neuropsychiatric symptoms as predictors of fatigue in post-COVID-19 condition, and stresses the importance of a holistic approach in assessing and considering potential treatment for COVID-19 patients experiencing fatigue.
    MeSH term(s) COVID-19/complications ; Cognition ; Cognitive Dysfunction/diagnosis ; Depression/diagnosis ; Fatigue/diagnosis ; Humans ; Quality of Life ; SARS-CoV-2
    Language English
    Publishing date 2022-04-30
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 187050-6
    ISSN 1432-1459 ; 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
    ISSN (online) 1432-1459
    ISSN 0340-5354 ; 0012-1037 ; 0939-1517 ; 1619-800X
    DOI 10.1007/s00415-022-11141-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Neuropsychological deficits in patients with cognitive complaints after COVID-19.

    García-Sánchez, Carmen / Calabria, Marco / Grunden, Nicholas / Pons, Catalina / Arroyo, Juan Antonio / Gómez-Anson, Beatriz / Lleó, Alberto / Alcolea, Daniel / Belvís, Roberto / Morollón, Noemí / Mur, Isabel / Pomar, Virginia / Domingo, Pere

    Brain and behavior

    2022  Volume 12, Issue 3, Page(s) e2508

    Abstract: Background: While much of the scientific focus thus far has been on cognitive sequelae in patients with severe COVID-19, subjective cognitive complaints are being reported across the spectrum of disease severity, with recent studies beginning to ... ...

    Abstract Background: While much of the scientific focus thus far has been on cognitive sequelae in patients with severe COVID-19, subjective cognitive complaints are being reported across the spectrum of disease severity, with recent studies beginning to corroborate patients' perceived deficits. In response to this, the aims of this study were to (1) explore the frequency of impaired performance across cognitive domains in post-COVID patients with subjective complaints and (2) uncover whether impairment existed within a single domain or across multiple.
    Methods: Sixty-three patients with subjective cognitive complaints post-COVID were assessed with a comprehensive protocol consisting of various neuropsychological tests and mood measures. Cognitive test performance was transformed into T scores and classified based on recommended guidelines. After performing a principal component analysis to define cognitive domain factors, distributions of test scores within and across domains were analyzed.
    Results: Results revealed pervasive impact on attention abilities, both as the singularly affected domain (19% of single-domain impairment) as well as coupled with decreased performance in executive functions, learning, and long-term memory. These salient attentional and associated executive deficits were largely unrelated to clinical factors such as hospitalization, disease duration, biomarkers, or affective measures.
    Discussion: These findings stress the importance of comprehensive evaluation and intervention to address cognitive sequelae in post-COVID patients of varying disease courses, not just those who were hospitalized or experienced severe symptoms. Future studies should investigate to what extent these cognitive abilities are recuperated over time as well as employ neuroimaging techniques to uncover underlying mechanisms of neural damage.
    MeSH term(s) COVID-19/complications ; Cognition/physiology ; Cognition Disorders/complications ; Cognitive Dysfunction/psychology ; Executive Function/physiology ; Humans ; Neuropsychological Tests
    Language English
    Publishing date 2022-02-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2623587-0
    ISSN 2162-3279 ; 2162-3279
    ISSN (online) 2162-3279
    ISSN 2162-3279
    DOI 10.1002/brb3.2508
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top